How the World’s Top Marijuana Stock Fell From Grace

After getting off to a good start in 2019, Canopy Growth Corp (TSX:WEED)(NYSE:CGC) has fallen from grace.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Canopy Growth (TSX:WEED)(NYSE:CGC) was once the world’s most beloved marijuana stock. After its $5 billion Constellation Brands deal, it went on a tear in the markets so pronounced, it lifted the rest of its sector with it. It’s hard to imagine now, but there was a time when many commentators believed Canopy was destined to soar to $100 and reach a market cap of $33 billion. In fact, it was at one point not far from hitting that milestone: its peak 2018 closing price was $73 and it had a market cap over $20 billion at that time.

That was then, this is now.

After the firing of its CEO and a $1.23 billion net loss, Canopy’s shares have been tanking hard. Down 14% for the full year and 51.9% from its peak price, WEED is about as bearish as they come. Although most marijuana stocks have been doing poorly this year, Canopy has been one of the worst. The following are three reasons why.

Ballooning expenses

It’s no secret that Canopy wasn’t profitable in its most recent quarter. In fact, with a $1.23 billion net loss, it was far from it. The lion’s share of Canopy’s enormous Q1 loss was warrant extinguishment, a one-time event that won’t recur. However, even the operating loss (which doesn’t include financing factors) was fairly large, coming in at $109 million.

A big reason for these losses is rising expenses. From Q2 to Q4, Canopy’s expenses grew from $234 million to $254 million, a sizable jump. However, those expenses fell to $200 million in Q1, so it’s possible that this long-term trend is starting to reverse.

Growth not matching competitors

The case for bullishness on marijuana stocks is based on one thing: growth. Almost none of these stocks are profitable, but most of them have revenue growth in spades. Canopy is no exception to this rule, having grown sales by 331% year over year in its most recent quarter. However, compared to ultra-high growers like Aphria, that’s not particularly great, especially when you consider that the company’s revenue growth will likely slow down as the one-time boost from legalization fades into the rear-view mirror.

Massive amounts of goodwill

A final factor that could be negatively affecting Canopy’s stock price is the goodwill on its books. Goodwill is generally defined as the premium a company pays for an acquisition above the target company’s book value. This “premium” can be kept on a company’s balance sheet as an asset, provided the asset is generating value for shareholders. However, accounting rules require that companies periodically “test” their goodwill to make sure it’s actually generating value for shareholders. If it’s not, then it may have to be written down.

As of its most recent quarter, Canopy had about $1.9 billion in goodwill on it books — the largest single category of assets it possessed. Should some of the company’s acquisitions prove to have been worthless, then much of that will have to be written down, drastically diminishing Canopy’s book value. If this comes to pass, then Canopy’s fall will likely continue.

Should you invest $1,000 in Cresco Labs right now?

Before you buy stock in Cresco Labs, consider this:

The Motley Fool Stock Advisor Canada analyst team just identified what they believe are the Top Stocks for 2025 and Beyond for investors to buy now… and Cresco Labs wasn’t one of them. The Top Stocks that made the cut could potentially produce monster returns in the coming years.

Consider MercadoLibre, which we first recommended on January 8, 2014 ... if you invested $1,000 in the “eBay of Latin America” at the time of our recommendation, you’d have $21,345.77!*

Stock Advisor Canada provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month – one from Canada and one from the U.S. The Stock Advisor Canada service has outperformed the return of S&P/TSX Composite Index by 24 percentage points since 2013*.

See the Top Stocks * Returns as of 4/21/25

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Andrew Button has no position in any of the stocks mentioned.

Confidently Navigate Market Volatility: Claim Your Free Report!

Feeling uneasy about the ups and downs of the stock market lately? You’re not alone. At The Motley Fool Canada, we get it — and we’re here to help. We’ve crafted an essential guide designed to help you through these uncertain times: "5-Step Checklist: How to Prepare Your Portfolio for Volatility."

Don't miss out on this opportunity for peace of mind. Just click below to learn how to receive your complimentary report today!

Get Our Free Report Today

More on Cannabis Stocks

Cannabis business and marijuana industry concept as the shadow of a dollar sign on a group of leaves
Stocks for Beginners

Buy the Dip Before It’s Too Late: This Canadian Stock Won’t Stay Cheap Forever

Investors might think that cannabis stocks are out, but this one could be the top Canadian stock to consider.

Read more »

a person watches a downward arrow crash through the floor
Stocks for Beginners

Plummet Alert: Is This TSX Growth Stock a Bargain or a Falling Knife?

This growth stock was once a major winner, but can investors wait for more?

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

What to Know About Canadian Cannabis Stocks for 2025

Let's dive into two top Canadian cannabis stocks and where they may be headed from here (given the recent moves…

Read more »

Researcher works in hemp field
Cannabis Stocks

Aurora Cannabis Stock Is up 46% in 2025: Are Investors Going From 5 Years of Pain to a 2025 Gain?

Shares of Aurora Cannabis have staged a comeback in 2025, outpacing the broader markets comfortably. Is ACB stock a good…

Read more »

A plant grows from coins.
Stocks for Beginners

3 Growth Stocks That Could Skyrocket in 2025 and Beyond

It could be a big year for these sectors, and these growth stocks in particular throughout 2025.

Read more »

money goes up and down in balance
Tech Stocks

2 TSX Stocks to Buy and 2 to Avoid in the Looming Trade War

The looming U.S.-Canada trade war has changed the business environment. Here are some TSX stocks to buy and avoid in…

Read more »

space ship model takes off
Cannabis Stocks

2 Canadian Stocks With Strong Momentum for 2025

Celestica Inc. (TSX:CLS) stock and Dollarama (TSX:DOL) stock have sustained strong price growth momentum for a long time.  Here’s why…

Read more »

Worker tags plants at an industrial cannabis operation
Cannabis Stocks

Pot Stocks: Buy, Sell, or Hold in 2025?

Cannabis stocks remain a bit risky, but could long-term investors be in for more pain or far more profits?

Read more »